{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-002189","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.232309+00:00","generated_at":"2026-05-28T22:40:40.513395+00:00","sec_items":["1.01","3.02","3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lipella Pharmaceuticals closes $2.23M initial tranche of Series B preferred offering","bullets":["Initial closing of $2.23M on Dec 23, 2024: 22,295 Series B shares sold at $100 each.","Net proceeds ~$1.8M; intended for working capital and general corporate purposes.","Series B convertible into 854,214 common shares at $2.61/share; 4.99% ownership cap.","Spartan Capital received ~$334K fees, 260,108 Series C conversion shares, and 85,421 warrants at $1.00.","Maximum offering size $6.0M (up to $7.2M with over-allotment); offering open until June 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-002189","json":"https://secwatch.observer/filing/0001753926-24-002189.json","markdown":"https://secwatch.observer/filing/0001753926-24-002189.md","text":"https://secwatch.observer/filing/0001753926-24-002189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392624002189/0001753926-24-002189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392624002189/g084615_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:40:40.513395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19d439369ac3996be12d5a7fddb99d141fd4c31a","claim":"LIPELLA PHARMACEUTICALS INC.: Filed Series B Certificate of Designation and Certificate of Correction, and Series C Certificate of Designation, establishing series preferred stock rights and preferences (effective 2024-12-20).","evidence_excerpt":"On December 23, 2024, the Company filed the Series C Certificate of Designation with the Delaware Secretary of State, establishing the rights, preferences, privileges, qualifications, restrictions, and limitations relating to the Series C Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347242/000175392624002189/0001753926-24-002189-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-12-20"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}